Combining Venetoclax and Azacitidine for treating Acute Leukemia of Ambiguous Lineage

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the efficacy and safety of combining venetoclax with azacitidine in patients newly diagnosed with Acute Leukemia of Ambiguous Lineage (ALAL). The study aims to improve remission rates and overall survival for this patient population, which currently has a poor prognosis. Participants will be closely monitored for treatment response and any adverse effects. The trial is designed for patients aged 15 to 65 who meet specific health criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients aged ≥ 15 years.
2. Patients diagnosed with ALAL according to 5th edition of WHO Acute Leukaemias of Ambiguous Lineage diagnosis standard.
3. New diagnosed patients.
4. ECOG performance status score less than 3.
5. Expected survival time ≥3 months.
6. Patients without serious heart, lung, liver, or kidney disease.
7. Ability to understand and voluntarily provide informed consent.

Exclusion Criteria:

1. Patients who are allergic to the study drug or drugs with similar chemical structures.
2. Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception.
3. Active infection.
4. Active bleeding.
5. Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment.
6. Patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met.
7. Liver function abnormalities (total bilirubin \> 1.5 times the upper limit of the normal range, ALT/AST \> 2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST \> 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine \> 1.5 times the upper limit of the normal value).
8. Patients with a history of clinically significant QTc interval prolongation (male \> 450 ms; female \> 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment.
9. Surgery on the main organs within the past six weeks.
10. Drug abuse or long-term alcohol abuse that would affect the evaluation results.
11. Patients who have received organ transplants (excepting bone marrow transplantation).
12. Patients not suitable for the study according to the investigator's assessment.

Where it's running

• The First Affliated Hospital of Soochow University
  Suzhou, China Recruiting

Study contacts

• Study coordinator: Sheng-Li Xue, MD
• Email: slxue@suda.edu.cn
• Phone: 0086-0512-67781139

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Choosing the Right Treatment Intensity for Adults with Acute Myeloid Leukemia and Myeloid Neoplasms

  This study tests whether a computer-guided randomization can help decide if a patient should receive higher- or lower-intensity chemotherapy when they’re not clearly fit, to see which approach is more helpful for adults with AML or related myeloid cancers.

  Recruiting Fred Hutchinson Cancer Center · Seattle, Washington · NCT07094750

• FLAG‑Ida chemotherapy followed by reduced‑intensity total‑body irradiation and donor stem cell transplant for adults 60+ with adverse‑risk AML or other high‑grade myeloid cancers

  This trial tests whether FLAG‑Ida chemotherapy given immediately before lower‑intensity total‑body radiation and a donor stem cell transplant can improve outcomes for adults 60 and older with newly diagnosed adverse‑risk acute myeloid leukemia or similar high‑grade myeloid cancers.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07046078

• Using revumenib to treat acute leukemia after stem cell transplant

  This study is testing a new drug called revumenib to see if it can help people with acute leukemia feel better after they’ve had a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06575296

• Restoring gut bacteria before stem cell transplant for blood cancer patients

  This study is testing if restoring gut bacteria with a special treatment before stem cell transplants can help blood cancer patients have better health and treatment outcomes.

  Recruiting at 6 sites Phase 2 Imperial College London · Birmingham, England and 7 other locations · NCT06355583

• Combining venetoclax and blinatumomab with standard chemotherapy for infants with acute leukemia

  This study is testing whether adding two new treatments, venetoclax and blinatumomab, to standard chemotherapy can help infants with acute leukemia do better and stay cancer-free longer.

  Recruiting at 117 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 116 other locations · NCT06317662

• Combining revumenib, azacitidine, and venetoclax for treating pediatric and young adult patients with tough cases of acute myeloid leukemia

  This study is testing a new combination of drugs to see if it can help young patients with tough cases of acute myeloid leukemia feel better and achieve remission.

  Recruiting at 10 sites Phase 1 St. Jude Children's Research Hospital · San Diego, California and 9 other locations · NCT06177067

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.